An observational study in Melanoma (Skin), sponsored by ECOG-ACRIN Cancer Research Group. Completed. Open to participants aged 18 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-19.
Sponsored by ECOG-ACRIN Cancer Research Group · Observational
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer, and may help doctors learn how well patients will respond to treatment.
PURPOSE: This laboratory study is looking at biomarkers to predict the response to interferon therapy in patients with melanoma.
OBJECTIVES:
OUTLINE: This is a multicenter study.
Serum samples are used for multiplex analyses. Biomarkers to be assessed include cytokines, chemokines, growth factors, angiogenic and antiangiogenic molecules, matrix metalloproteases (MMPs), tissue inhibitors of MMPs (TIMPs), melanoma-associated antigens, basic fibroblast growth factor, insulin-like growth factor I and II, thrombospondin, endostatin, angiostatin, vasostatin, and vascular endothelial growth factor inhibitor.
PROJECTED ACCRUAL: A total of 1,716 samples will be accrued for this study.
3,006 studies on the registry are indexed under Melanoma; 520 are open to participants now.
This study's enrollment of 1,716 is above the median of 182 across 438 observational studies indexed under Melanoma.
Browse Melanoma studies →ECOG-ACRIN Cancer Research Group is the lead sponsor of 118 studies on the registry; 13 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Samples submitted for research from patients participating in E1690 and E1694
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Generation of a comprehensive multiplexed array of melanoma-associated serological markers
Generation of a comprehensive multiplexed array of melanoma-associated serological markers
Time frame: 1 month
Changes in the profile of serological markers induced by interferon-alfa 2b therapy
Changes in the profile of serological markers induced by interferon-alfa 2b therapy
Time frame: 1 month
Panels of serological markers with prognostic and predictive power for interferon-alfa 2b response
Panels of serological markers with prognostic and predictive power for interferon-alfa 2b response
Time frame: 1 month
No study locations are listed for this record.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ECOG-ACRIN Cancer Research Group